TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05033847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (CHO cell)
Description: Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (CHO cell)
Description: Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (CHO cell)
Description: Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine (Vero cells)
Description: Intramuscular injection of Recombinant COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine (Vero cells)
Description: Intramuscular injection of Recombinant COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine (Vero cells)
Description: Intramuscular injection of Recombinant COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
Study: NCT05439109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topographical landmark technique of endotracheal tube placement
Description: An endotracheal tube will be placed inside the trachea after measuring the individual's estimated tracheal dimensions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation guide mark technique of endotracheal tube placement
Description: An endotracheal tube will be placed in this group by using the intubation guide mark.
Study: NCT06558656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTQ5082 capsule
Description: Part 1:The subjects are orally administered NT5082 capsules on an empty stomach in the first cycle and after a meal in the second cycle.~Part 2:The subjects are orally administered NT5082 capsules after a meal in the first cycle and on an empty stomach in the second cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTQ5082 capsule
Description: Part 1:The subjects are orally administered NT5082 capsules on an empty stomach in the first cycle and after a meal in the second cycle.~Part 2:The subjects are orally administered NT5082 capsules after a meal in the first cycle and on an empty stomach in the second cycle.
Study: NCT05104125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC40 25mg
Description: 25mg of ASC40 orally once daily for 12 weeks.
Study: NCT06372353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin Exercise
Description: Baduanjin exercise training program was applied to the subjects in the exercise group, 3 days a week, 5 minutes each with warm-up and cool-down exercises, for a total of 24 sessions, 60 minutes each, under supervision, online, via the ZOOM application, for 8 weeks. In addition, the patients did the exercises unsupervised at home once a week. The patients' first sessions were held in the hospital
Study: NCT05013372

Intervention type: DRUG
Group type: OTHER
Intervention: CD147- CAR T cells
Description: CAR T cells targeting CD147
Study: NCT06339515

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Universal Design Model
Description: Universal design-based learning is based on the application of universal design approach principles to education. Universal design-based learning considers three broad networks of the brain to enable learning. These are recognition networks, strategic networks and affective networks. Universal design-based learning is a student-centered approach and curricula are designed to appeal to all students. Curricula consist of objectives, teaching methods, teaching materials and assessment and evaluation elements. Students' interests, needs and abilities are taken into consideration when designing curricula. Students' learning disabilities are identified and alternative practices are planned to eliminate these disabilities. All students are given equal opportunity to learn
Study: NCT05104125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC40 50mg
Description: 50mg of ASC40 orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC40 75mg
Description: 75mg of ASC40 orally once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally once daily for 12 weeks.
Study: NCT05291702

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PCNL
Description: Percutaneous nephrolithotomy ( Extraction of the renal stones using the nephroscope/ Ureteroscope )
Study: NCT06263972

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Stimulation Prefrontal Cortex
Description: The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation to prefrontal cortex for 3 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Shame cortex stimulation
Description: The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with shame low current electrical stimulation to cortex for 3 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Stimulation to Motor Cortex
Description: The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation to Motor cortex for 3 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: erobic physical activity
Description: Aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment),

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: erobic physical activity
Description: Aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment),

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: erobic physical activity
Description: Aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment),
Study: NCT04571658

Intervention type: OTHER
Intervention: Communication
Description: The NEPTUNE Match study includes an interdisciplinary Communication Team that will translate findings from the Molecular Nephrology Board (MNB) to inform patients of the matching assessment with ongoing clinical trials. This team has considerable experience with conveying complex biomedical research information to patients and families and includes experts in precision nephrology, nephrology patient \[adult and pediatric\] communication, and health education.
Study: NCT05757908

Intervention type: DRUG
Group type: OTHER
Intervention: Long-Acting Beta Agonist
Description: The Investigator will prescribe standard of care LABA to eligible study participants. Participants will self-administer LABA once or twice daily at the maximum feasible standard of care dosage, per the time points specified in the study Schedule of Assessments. LABA should be taken within 1 to 3 hours prior to morning and evening at-home mobile Spirometry testing.
Study: NCT06388122

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05218486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
Study: NCT04452175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL E-CIGARETTE
Description: JUUL E-CIGARETTE USAGE FOR 24 WEEKS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: JUUL E-CIGARETTE
Description: JUUL E-CIGARETTE USAGE FOR 24 WEEKS
Study: NCT06340659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HbAEx
Description: Participants will have a 1-week (3 session) on-boarding period where study interventionists will deliver all necessary equipment (bike, pulse oximeters, etc.) to the participants' home, review the AEx program and prescription, and supervise the first 3 sessions to ensure participant understanding and fidelity of the AEx program. Thereafter, the remaining 33 sessions will be conducted by the participant without the direct supervision (asynchronous telerehabilitation) of the study interventionists. Subjects will cycle on recumbent stationary cycles at moderate-vigorous intensity individualized as 50-70% of heart rate reserve (HRR) and/or 11-14 on Borg Category Ratio-15 Rating of Perceived Exertion (RPE) Scale, for 30-50 minutes per session. Following the completion of each session, during the check-in meeting with the participant, the study interventionist will gather information from the participant (including HR and RPE) for dose quantification.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HbExergame
Description: Participants will cycle as described in the HbAEx protocol while engaging in cognitive training for the duration of cycling. Cognitive training will include 20 levels of difficulty with 8-10 task scenarios in the context of three virtual worlds (environments. In each of the environments, the participant must follow directions and navigate to a destination where the scenario (cognitive task) will be performed. The game will inform the participant of the assigned task and, automatically, determine and inform the participant of the fastest route from the starting point to the scenario destination where the task will be performed. The participant will be required to remember the assigned task, follow the directions and navigate to the destination, and then remember what action is required to complete the task. A scenario-specific cognitive task will be triggered once the destination has been reached. The cycling and cognitive tasks will be completed throughout the sessions.
Study: NCT05293886

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical Pelvic Floor Muscle Training
Description: In the first 2 weeks of classical pelvic floor muscle training, individuals will perform 3 sets of 10 maximal voluntary pelvic floor muscle contraction exercises and 20 submaximal voluntary pelvic floor muscle contraction exercises per day. In every 2-week control, the number of sets will be increased by one set.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Pelvic Floor Muscle Training
Description: Functional pelvic floor muscle training will be started with 3 exercises (toe tap, bridge and clamshall exercises), each exercise will be performed with 1 set and 30 repetitions. In every 2-week control, the number of exercises will be increased by one. Cat-cow exercise will be added at 3-4th weeks, squats will be added at 5-6th weeks, and lunges will be added at 7-8th weeks.
Study: NCT04959513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LPRF bone block
Description: Guided bone regeneration using an L-PRF bone block (composite graft composed of a xenograft, a membrane from the patient's blood and a collagenous membrane) after a short healing period of 6 to 8 weeks after tooth extraction
Study: NCT06530329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical massage
Description: Classical massage was started by general stroking 3 times. Then, it was continued by kneading 3 times. After the kneading movement, fibrocytic nodules on the muscle were searched and friction was applied to the found nodules one by one. The massage of the muscle was completed by applying stroking 3 times. The application was carried out 3 times a week for 2 weeks to evaluate the short-term effect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical massage
Description: Classical massage was started by general stroking 3 times. Then, it was continued by kneading 3 times. After the kneading movement, fibrocytic nodules on the muscle were searched and friction was applied to the found nodules one by one. The massage of the muscle was completed by applying stroking 3 times. The application was carried out 3 times a week for 2 weeks to evaluate the short-term effect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression
Description: Ischemic compression was applied to the trigger points in the upper trapezius muscle using an average pressure of 1 kg at a right angle, and after compression, passive stretching was applied to the upper trapezius muscle 3 times in 20-second periods. The application was performed 3 times a week for 2 weeks to evaluate the short-term effect.
Study: NCT05830747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pre-operative drug administration before third molar surgery
Study: NCT05424393

Intervention type: DRUG
Intervention: YISAIPU® ( An etanercept biosimilar)
Description: YISAIPU®, an etanercept biosimilar produced by 3SBio Inc., is a TNF-α inhibitor targeting soluble TNF-α to inhibit its interaction with cell-surface receptors. It has been widely used in clinical practice for 17 years in China. According to the prescription information, YISAIPU should be given as 25mg, biw, pc.

Intervention type: DRUG
Intervention: csDMARDs
Description: csDMARDs include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide The use of csDMARDs complies with clinical routine practice and treatment strategy of treat-to-target.
Study: NCT05092607

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venous and Capillary blood sampling
Description: Venous sample at the bend of the elbow (7mL) taken immediately after the nasopharyngeal sample.~Capillary blood sampling, for patients included in participating centers
Study: NCT06390670

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colostrum Bovinum supplementation
Description: In the experimental procedure each athlete was supplemented with a chronic dose of 25 g/day of COL. Supplement was particularly prepared for the study from a first post-delivery milking and had a high content of IgG (60%; certified Colostrum Bovinum; Agrapak, Poland). The COL was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the COL supplement in 250 mL of plain water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: In the control procedure each athlete was supplemented with a chronic dose of 25 g/day of placebo (PLA). PLA was particularly prepared for the study, and was an isoenergetic/isomacronutrient product (high quality protein) prepared for the trial (Agrapak, Poland). The PLA was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the PLA preparation in 250 mL of plain water.
Study: NCT05830747

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pre-operative Placebo administration before third molar surgery
Study: NCT04470895

Intervention type: DIAGNOSTIC_TEST
Intervention: Failure Track patients analysis
Description: The nurse coordinator of the Fracture Track first comes to give the patient a written information note. She answers the patient's questions and obtains his or her non-opposition. The patient must be given sufficient time for reflection to make his decision in order to participate in the study. His non opposition will be traced in the computerized medical record. Each enrolling patient in the study can simultaneously participate in another research. There is no exclusion period in the protocol.~Once the patient is included, a semi-directed interview is conducted. The name of the patient's usual pharmacy will be collected. Data from the computerised medical record concerning the patient's stay are also analysed.~The patient's usual pharmacy or the nurse in charge of the patient will then be questioned in order to carry out a drug reconciliation interview.

Intervention type: DIAGNOSTIC_TEST
Intervention: Failure Track patients analysis
Description: The nurse coordinator of the Fracture Track first comes to give the patient a written information note. She answers the patient's questions and obtains his or her non-opposition. The patient must be given sufficient time for reflection to make his decision in order to participate in the study. His non opposition will be traced in the computerized medical record. Each enrolling patient in the study can simultaneously participate in another research. There is no exclusion period in the protocol.~Once the patient is included, a semi-directed interview is conducted. The name of the patient's usual pharmacy will be collected. Data from the computerised medical record concerning the patient's stay are also analysed.~The patient's usual pharmacy or the nurse in charge of the patient will then be questioned in order to carry out a drug reconciliation interview.
Study: NCT04996056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-1300
Description: TNX 1300 200 mg Intravenous injection
Study: NCT05254301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: This personalised multimodal treatment considers evidence- and practice-based elements (e.g., self-management, individual guidance \& follow-up, low-threshold activities, homebased functional training \& better follow-up guidance afterwards).
Study: NCT04996056

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual Care per the Emergency Department protocol for Cocaine Intoxication
Study: NCT05372809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SkinTE
Description: SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard care is defined in this protocol to include the following:~* Debridement~* Collagen-alginate primary wound dressing~* Local offloading with felt pad for wounds on weight bearing surfaces~* Foam~* Multi-layer compression dressing~* Off-loading device such as a full-length boot or total contact cast (if full-length boot cannot accommodate the patient) or surgical shoe for ulcers in non-weight bearing locations
Study: NCT06417632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Zirconia Crown
Description: monolithic implant supported crown

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Zirconia Crown
Description: monolithic implant supported crown
Study: NCT06638112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachial Plexus Block
Description: Interscalene brachial plexus block with 0.75% ropivacaine. Intraoperative sedation with remimazolam.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia (control group)
Description: General anesthesia with propofol, fentanyl and rocuronium for induction, and with sevoflurane for maintenance. Brachial plexus block with 0.5% ropivacaine for intra- and postoperative analgesia.
Study: NCT06412341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accepting your Body after Cancer
Description: See 'Arm Description'

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Macmillan body image booklet
Description: See 'Arm Description'

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Macmillan body image booklet
Description: See 'Arm Description'
Study: NCT05987644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: 600mg taken orally, twice daily for 25 Cycles Cycle = 4 weeks (28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: 600mg taken orally, twice daily for 25 Cycles Cycle = 4 weeks (28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: 600mg taken orally, twice daily for 25 Cycles Cycle = 4 weeks (28 days)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: SRS dose varies by brain met size and location
Study: NCT04547257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seraph 100
Description: Bloodfiltration with Seraph 100
Study: NCT05254301

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: This personalised multimodal treatment considers evidence- and practice-based elements (e.g., self-management, individual guidance \& follow-up, low-threshold activities, homebased functional training \& better follow-up guidance afterwards).
Study: NCT04404335

Intervention type: DIAGNOSTIC_TEST
Intervention: Crevicular fluid analysis by using ELISA testing.
Description: Samples of crevicular fluid (fluid existing in the space between the gums and the roots of the teeth) will be obtained from healthy and periodontal patients. In periodontal patients, samples will be taken before and after receiving a routine course of periodontal treatment (root scale and polish) to assess the levels of a peptide called LL-37 and inflammatory cytokines (IL-4, IL-6, IL-10): Samples will then be analysed using laboratory procedures (ELISA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Crevicular fluid analysis by using ELISA testing.
Description: Samples of crevicular fluid (fluid existing in the space between the gums and the roots of the teeth) will be obtained from healthy and periodontal patients. In periodontal patients, samples will be taken before and after receiving a routine course of periodontal treatment (root scale and polish) to assess the levels of a peptide called LL-37 and inflammatory cytokines (IL-4, IL-6, IL-10): Samples will then be analysed using laboratory procedures (ELISA)